Cobetia marina polysaccharide P268 for dry eye treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases such as dry eye syndrome and inflammation lack effective solutions, particularly in addressing the symptoms of ocular dryness, burning, and fatigue associated with environmental factors and minor complaints.
Innovation Solution
A polysaccharide derived from the Cobetia marina bacterial strain, specifically P268, is used in compositions for ocular applications, comprising monomers like rhamnose, glucose, galactose, galacturonic acid, and N-acetyl-glucosamine, with sulfated hydroxyl groups and a molecular weight range of 1,000,000 to 10,000,000 g/mol, formulated into eye drops, artificial tears, or ointments to treat dry eye conditions and inflammatory ocular issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for ocular diseases, then general symptom management is provided, but effective treatment of ocular dryness, burning, and fatigue symptoms is lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of polysaccharides through controlled sulfation (10-20% of hydroxyl groups sulfated) and selecting specific molecular weight ranges (1,000,000 to 10,000,000 g/mol). These parameter modifications enhance the polysaccharide's ability to retain moisture and reduce inflammation, directly addressing ocular dryness and inflammation symptoms that conventional treatments fail to effectively manage.
2Reliability
If polysaccharide with specific molecular weight and sulfation is used, then treatment effectiveness for dry eye and inflammation is improved, but manufacturing complexity increases
Solution Approach 1:
The patent specifies precise parameter ranges for the polysaccharide including molecular weight (1,000,000 to 10,000,000 g/mol), sulfation degree (10-20% of hydroxyl groups), and monomer composition ratios. These defined parameters provide clear manufacturing targets that balance treatment effectiveness with manufacturability, allowing producers to optimize processes within specified ranges rather than requiring absolute precision.
Solution Approach 2:
The patent utilizes composite materials by combining multiple monomer units (rhamnose, glucose, galactose, galacturonic acid, and N-acetyl-glucosamine) into a complex polysaccharide structure with specific sulfation patterns. This composite structure provides enhanced therapeutic effects for ocular conditions while the defined composition ranges facilitate standardized production processes.
Data Source
AI summary
The use of a polysaccharide derived from a bacterial strain in the prevention of ocular diseases and the treatment of ocular diseases. Especially, the ophthalmic use of a polysaccharide susceptible to be obtained from the CNCM I-5038 Cobetia marina bacterial strain in ocular conditions associated with ophthalmic dryness and ophthalmic inflammation.